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Abstract
Objectives: The therapeutic utility of hypoxia-inducible factor-1 (HIF-1) transcriptional regulatory system for ischemic hindlimb has
been demonstrated. It is not yet known whether this transcriptional regulatory system can be used as a therapeutic strategy to enhance
collateral vessel formation in myocardial tissues, where acute hypoxia occurs due to inadequate perfusion.We aimed to test the hypothesis
that exogenous administration of HIF-1a/VP16 could enhance collateral vessel formation in a rat acute myocardial infarction model.
Methods: Sprague–Dawley rats received ligation of the proximal left anterior descending coronary artery to induce acute myocardial
infarction. Immediately after the ligation, 50 mg total plasmid DNA (control, plasmid encoding human vascular endothelial growth factor
(pVEGF ), or pHIF-1a/VP16) was injected into the infarct area at three locations. Results: Reverse transcription–polymerase chain 165
reaction (RT–PCR) showed the presence of HIF-1a and VEGF mRNA in the myocardium, but not in other organs at days 3 and 7. The
infarct size signiﬁcantly decreased from 3764% (control) to 2462% in theVEGF-treated group and 2362% in the HIF-1a/VP16 treated
22 group (P,0.05). Capillary density also signiﬁcantly increased from 550675/mm (control) to 850675/mm in the VEGF group and
2 850650/mm in the HIF-1a/VP16-treated group (P,0.01). Combined therapy with HIF-1a/VP16 and VEGF resulted in higher
2 capillary density (1230650/mm ) than treatment with either therapy alone. Regional myocardial blood ﬂow was also higher in the treated
groups than in the control. Plasma levels of VEGF were also signiﬁcantly higher in the HIF-1a/VP16 and VEGF-treated group than in
the control group. Conclusions: The HIF-1a/VP16 hybrid transcription factor is able to reduce infarct size and enhance neovasculariza-
tion in an acute ischemic myocardium. The potency of VEGF and HIF-1a/VP16 hybrid as therapeutic angiogenic factors in acute
hypoxic myocardium is similar. Ó 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction [3,4], and diabetic neovascularization [5]. Hypoxia also
plays a signiﬁcant role in regulating angiogenesis and
New blood vessel formation has been recognized as an vasoformation during mammalian embryonic development
adaptive response to cellular hypoxia [1]. In the case of [6].VEGF is a protein that is essential for angiogenesis [7].
local hypoxia due to inadequate perfusion (ischemia), Increased expression of VEGF gene in hypoxic cells is
angiogenesis is stimulated by the production of vascular mediated in part by increased gene transcription [8–11].
endothelial growth factor (VEGF), a well-known phenom- Transcription of genes encoding erythropoietin,VEGF, and
enon in coronary artery disease [2], tumor angiogenesis glycolytic enzymes is activated in hypoxic cells by a
common molecular mechanism [12]. Transcriptional acti-
vation of these genes is mediated by the binding of *Corresponding author. Tel.: 1886-2-2833-2211; fax: 1886-2-2836-
5775.
E-mail address: m001043@ms.skh.org.tw (H. Chang). Time for primary review 22 days.
0008-6363/02/$ – see front matter Ó 2002 Elsevier Science B.V. All rights reserved.
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hypoxia-inducible factor 1 (HIF-1) to cis-acting hypoxia- was tightened around the proximal left anterior descending
response elements located primarily within 59-ﬂanking coronary artery (before the ﬁrst branch of diagonal artery).
regions of these genes [13]. These observations suggest Positive end-expiratory pressure was applied to fully
that activation of HIF-1 may be involved in the regulation inﬂate the lungs. The muscle layer and skin were closed
of vascular growth and cellular metabolism. separately after plasmid injection, and the animals were
HIF-1, a DNA binding complex ﬁrst identiﬁed as a allowed to recover. The experimental protocol was ap-
factor critical for the inducible activity of the erythro- proved by the Shin Kong WHS Memorial Hospital com-
poietin 39 enhancer [14], is a key physiological regulator of mittee on animal experiments.
gene expression that responds to changes in cellular
oxygen tension [15]. HIF-1 is a heterodimeric DNA 2.2. Plasmids
complex composed of two basic helix-loop-helix Per-
AHR-ARNT-Sim-proteins (HIF-1a and HIF-1b) [16]. The HIF-1a/VP16 plasmid was generated by Genzyme
HIF-1a protein levels, which determine the level of HIF-1 Corporation (Framingham, MA, USA). cDNA fragments
DNA-binding and transcriptional activity, increases ex- of HIF-1a at amino acid (aa) 390 as well as VP16 C-
ponentially as cellular oxygen concentration is reduced terminal aa 413–490 were assembled into a simple eukary-
[17]. Under hypoxic conditions, both HIF-1a protein level otic expression plasmid that uses a CMVpromoter to drive
and the activity of the HIF-1a transactivation domains HIF-1a expression. Downstream from the HIF-1a cDNA
increase [17,18]. Pugh et al. demonstrated that sequences is a BGH polyadenylation sequence. These fragments
from HIF-1a but not HIF-1b convey hypoxia-inducible occur in the pUC19 vector, which includes an SV40-neo
activity when fused to the DNA binding domain of gene for neomycin resistance. The plasmid pCMVb encod-
heterologous transcription factors [19]. The HIF-1 gene ing b-galactosidase under control of CMV promoter/en-
has been shown to be involved in tumor angiogenesis and hancer was used for the control transfection experiments.
growth [20–22]. The therapeutic utility of this transcrip- Plasmids were puriﬁed with QIAGEN kits. Ethanol pre-
tional regulatory system for targeting gene expression at cipitation was used to sterilize all plasmids in preparation
hypoxic tumor cells or ischemic hindlimb has been demon- for myocardial injection, after which, the DNA pellets
strated [22,23]. However, it is not known whether this were reconstituted with sterile PBS containing 5% sucrose,
transcriptional regulatory system can be used as a thera- and stored at 220 8C. Prior to injection, DNA concen-
peutic strategy to enhance collateral vessel formation in trations were determined by a spectrophotometer. The
myocardial tissues where acute hypoxia occurs due to plasmid constructs phVEGF and pCMVb have been 165
inadequate perfusion. previously described [25].
The HIF-1a/VP16 hybrid is a constitutively active and
more potent form of HIF-1a by constructing a hybrid 2.3. Intramyocardial gene transfer
transcription factor consisting of the DNA-binding and
dimerization domains from HIF-1a and the transactivation After ligation of the left anterior descending coronary
domain from herpes simplex virus VP16 protein [24]. The artery, 50 mg of total plasmid DNA in 0.1 ml of normal
HIF-1a/VP16 hybrid up-regulates exogenous VEGF ex- saline were injected intramuscularly at the left anterior free
pression in vitro and enhances angiogenesis in rabbit wall by using an insulin syringe with a 30-gauge needle.
hindlimb ischemia [23]. After the left ventricle was accessed, the needle was
Accordingly, we ought to test the hypothesis that advanced along the left ventricular free wall and plasmid
exogenous administration of HIF-1a/VP16 hybrid could DNA was injected over a period of 5 to 10 s at three
enhance collateral vessel formation in a rat acute myocar- separate sites. The injected sites were chosen at least 5 mm
dial infarction model and to compare the potency of away from the left ventricular apex. All animals received
HIF-1a/VP16 hybrid to that of VEGF as a therapeutic three intramyocardial injections of plasmid, with the
angiogenic factor. control plasmid being pCMVb. In the treated animals,
pHIF-1a/VP16 or phVEGF was injected. After injec- 165
tion, the chest was closed and the animals were allowed to
2. Methods recover.
2.1. Production of acute myocardial infarction 2.4. b-Galactosidase gene expression
Male Sprague–Dawley rats weighing 250–350 g were To localize the areas of injection and reporter gene
intraperitoneally anesthetized with sodium pentobarbital expressions relative to the infarcts, b-galactosidase activity
(45 mg/kg). The rats were intubated and ventilated with a was assessed by incubating muscles in 5-bromo-chloro-3-
volume-cycled small-animal ventilator. An anterior indolyl-b-D-galactosidase chromogen (X-Gal, Sigma, St.
thoracotomy was performed to open the pericardium. The Louis, MO, USA) overnight at 37 8C after intramyocardial
heart was then rapidly exteriorized, and a 6-0 silk suture injection of pCMVb in four additional rats. After staining,
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the muscles were rinsed in saline, post-ﬁxed in 1% septum were separated and weighed. The tissues were then
paraformaldehyde, and were then parafﬁn embedded, immersed and ﬁxed in 10% buffered formalin. Each heart
sectioned, and counterstained with hematoxylin and eosin. was sliced in cross section at four levels spanning from the
Five sections from each sample were randomly selected, apex to the base and prepared for routine histology. These
and the numbers of positive and total myocytes in ﬁve sections from each level were stained with 1% tri-
high-power ﬁelds among an area including pericardium phenyltrtrazolium chloride (TTC) for 20 min. The his-
were counted manually for each specimen. tological sections of all four slices were projected on a
digitalization screen. A planimeter was used to obtain the
length of the entire endocardial circumference and that 2.5. Human VEGF and HIF-1 gene expression in
segment of the endocardial circumference made up by the
ischemic myocardial muscles
infarcted portion from each of the four slices of the left
ventricle. The infarct size, expressed as a percentage of the
Gene expression was evaluated by detecting mRNA
left ventricle, was calculated by dividing the circumference
levels using RT–PCR with rats of myocardial infarction
of the infarct by the total circumference of the left
that were put to death at days 1, 3, 7, 14 and 28 after the
ventricle including the septum. The person who measured
transfection with phVEGF and HIF-1a/VP16 hybrid 165 the infarct size was unaware of the treatment group.
(n52 at each time point) or control plasmid (n52a t7
days after transfection). In the eight rats killed at 3 and 7
days after transfection, remote tissues (lung, liver, spleen, 2.7. Capillary density by immunohistochemistry
and aorta) were also retrieved for analysis of humanVEGF
and HIF-1a mRNA. To ensure speciﬁcity and avoid
At the day of sacriﬁce (days 14 and 28 after transfection,
ampliﬁcation of endogenous rat VEGF and HIF-1, each
respectively), the left ventricle was harvested, ﬁxed in
primer was selected from a region that was not conserved
methanol, and sliced into 5 mm parafﬁn sections. To block
among different species. Sequences of primers used for
endogenous peroxide activity and nonspeciﬁc binding,
VEGF were 59-GAGGGCAGAATCATCACGAAGT-39
sections were incubated with 3% hydrogen peroxide
(sense) and 59-TGAGAGATCTGGTTCCCGAAAC-39
followed by 10% normal horse serum. Specimens were
(antisense). Sequences of primers used for HIF-1a were
incubated with a monoclonal anti-mouse CD31 antibody at
59-AGAAAAAGATAAGTTCTGAACGTC-39 (sense) and
4 8C overnight. Bound primary antibodies were detected
59-GAGAAAAAAGCTTCGCTGTGTG-39 (antisense).
with the avidin–biotin–immunoperoxidase method (Sig-
RT–PCR was performed according to the manufacture’s
net). Nonimmune normal rabbit IgG was used to conﬁrm
protocol (Access RT–PCR System, Promega, Madison,
speciﬁcity. The number of capillaries was counted in
WI, USA). The size of the PCR product for VEGF and
regions with transversely sectioned myocytes in the border
HIF-1a was 531 and 478 bp, respectively. RT–PCR
zone and in the area of infarction. Twenty sections per
products were analyzed by 2% agarose gel electrophoresis.
heart were evaluated to estimate capillarity by another
To detect the endogenous gene response to the ischemic
investigator unaware of the treatment groups. Five ﬁelds
change, real time PCR using a Lightcycler (Roche Diag-
per section were randomly selected and analyzed at a
nostics, Mannheim, Germany) was performed with rat
magniﬁcation of 4003. The number of capillaries was
speciﬁc primers for VEGF and HIF-1a. Sequences of
assessed from photomicrographs by computerized image
primers used for rat VEGF were 59-CACCCAC-
analysis.
GACAGAAGG-39 (sense) and 59-TCACAG-
TGAACGCTCC-39 (antisense). Sequences of primers used
for rat HIF-1a were 59-AGTCGGACAGCCTCAC-39 2.8. Myocardial perfusion detection
(sense) and 59-TGCTGCCTTGTATGGGA-39 (antisense).
The initial denaturation phase was 10 min at 95 8C
At day 28 after transfection, animals were reanesthetized
followed by an ampliﬁcation phase as described below:
and their chests were opened. Radioactive microspheres
denaturation at 95 8C for 10 s; annealing at 55 8Cf o r5s ;
(PerkinElmer Life Sciences, Inc., Boston, MA, USA),
elongation at 72 8C for 15 s and for 30 cycles. Ampliﬁca- 141 approximately 700 000 in number, labeled with Cr,
tion, ﬂuorescence detection, and post-processing calcula-
were injected into the left ventricular cavity. The micro-
tions were also performed using the Lightcycler apparatus.
spheres were allowed to circulate for 1 min. Then, the
animals were euthanized, and the hearts were excised.
2.6. Infarct size determination Tissue specimens from the left ventricle including the
septum and right ventricular free wall were excised for
Two weeks after myocardial infarction, rats were deeply measurement of radioactivity. The activities in the left
anesthetized with pentobarbital and put to death by rapid ventricle were expressed per weight of heart tissue as a
excision of the heart. The atria were trimmed from the ratio relative to the activity in the right ventricular free
ventricles, and the right ventricle and left ventricle plus wall.
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purchased for R&D Systems. The lower limit of detection
of plasmaVEGF was 5 pg/ml. The assay was performed in
duplicate for each sample.
2.10. Statistical analysis
All results were expressed as mean6S.E.M. Statistical
signiﬁcance was evaluated by analysis of variance fol-
lowed by Scheffe’s procedure. A value of P,0.05 was
considered to denote statistical signiﬁcance.
3. Results
3.1. Evidence of transfection
To demonstrate the activity of reporter genes, X-Gal
staining was performed 4 days after intramyocardial Fig. 1. Expression of b-galactosidase in the ischemic myocardium.
injection. In the myocardium transfected with pCMVb, Positive expression is identiﬁed as dark-blue staining of myocytes
successful transfection was evidenced by dark-blue stains (arrow).
that were observed at the area near the infarct size, but not
in the infarct area (Fig. 1). This evidence showed that the
2.9. Measurement of plasma VEGF plasmids were delivered into the peri-infarct zone. The
efﬁciency of gene transfer using b-galactosidase detection
For the ﬁrst six rats in each group, blood samples were was 3.660.5%.
drawn from the left carotid artery at day 3 and from the
right femoral artery at day 7 using a 23-gauge needle after 3.2. Human HIF-1a/VP16 and VEGF gene expression
coronary ligation. After sampling 0.5 ml of blood, the left in myocardium
carotid and right femoral arteries were ligated. The blood
sample was stored at 4 8C for 30 min and then centrifuged To conﬁrm HIF-1a/VP16 and VEGF gene expression in
at 3000 rev./min for 15 min. Plasma was frozen at 280 8C the transfected rat myocardium, we analyzed the gene
until assay of VEGF by a mouse VEGF ELISA kit, expression of transfected myocardium by detecting mRNA
Fig. 2. Expression of human HIF-1a and VEGF mRNA by RT–PCR in ischemic myocardium. (A) Human HIF-1a and VEGF mRNA expression at
different periods of time. M, Promega 100-bp DNA ladder; H1 and V1, positive control for HIF-1a and VEGF, respectively; H , H , H , H , and H , 1371 4 2 8
ischemic myocardium transfected with pHIF-1a/VP16 at days 3, 7, 14, and 28;V ,V ,V ,V and V , ischemic myocardium transfected with phVEGF at 1371 4 2 8 165
days 1, 3, 7, 14 and 28; Corresponding b-actin expression is indicated below. (B) No expression of human HIF-1a and VEGF mRNA at extramyocardial
tissues. M, Promega 100-bp DNA ladder; 1, positive control; 1, 4, 7, 10, and 13, brain, lung, liver, kidney and limb muscle, respectively, from rats
transfected with pHIF-1a/VP16 at day 7; 2, 5, 8, 11, and 14, brain, lung, liver, kidney and limb muscle, respectively, from rats treated with phVEGF ; 3, 165
6, 9, 12, and 15, same tissue as mentioned above from rats treated with pCMVb. Corresponding b-actin expression is indicated below.
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using RT–PCR. HIF-1a and VEGF mRNA were detected
in the myocardium at days 1, 3, 7 and 14 after gene
transfection (Fig. 2). The mRNA of HIF-1a and VEGF
could not be detected at day 28 after transfection. Neither
HIF-1a nor VEGF mRNA was detected in distal tissues at
days 3 and 7. Rat myocardium injected with pCMVb
plasmid was consistently negative for HIF-1a and VEGF
mRNA. To detect the endogenous gene response to the
ischemic change, real time PCR using a Lightcycler
(Roche Diagnostics, Mannheim, Germany) was performed
with rat speciﬁc primers for VEGF and HIF-1a. The
mRNA of endogenous VEGF at day 7 after infarction in
the pHIF-1a/VP16, phVEGF , and pCMVb-treated 165
groups increased 2.4-, 4.2-, and 2.1-fold, respectively as
compared to the normal rat without infarction. The mRNA
of endogenous HIF-1a at 7 days after infarction in the
pHIF-1a/VP16, phVEGF , and pCMVb-treated groups 165
increased 4.3-, 3.8-, and 2.8-fold, respectively as compared
to the rat without infarction.
Fig. 3. Effect of intramyocardial pHIF-1a/VP16 and phVEGF hybrid 165
on infarction ratio. The number of rats used in this analysis was nine in 3.3. Infarct size each group. The infarction ratio represents infarction area divided by total
left ventricular area.
Since the infarct size of the rats transfected with
pCMVb was similar to that of rats transfected with saline
only (data not shown), we used pCMVb-treated rats as the or phVEGF -treated group. The capillary density was 165
control. A total of 44 rats were studied for the determi- similar between the HIF-1a/VP16-treated and VEGF-
nation of infarct size with surgical mortality rates after treated groups. The capillary density of the control group
coronary ligation and intramyocardial injection at 31% in (pCMVb) was signiﬁcantly higher than that of the rat
each group. Measurement of the infarct size of the left without infarction (data not shown). The capillary densities
ventricle was performed in 31 hearts (four pHIF-1a/VP16 at day 14 after transfection were also signiﬁcantly higher
plus phVEGF -treated hearts, nine pHIF-1a/VP16- (P,0.05) in the pHIF-11a/VP16-treated group (650650/ 165
2 2 treated hearts, nine phVEGF -treated hearts and nine mm ) and the phVEGF -treated group (625650/mm ) 165 165
2 controls) at day 14 after transfection. Infarct size was than in the control (400675/mm ). Grossly and micro-
signiﬁcantly smaller in the pHIF-1a/VP16-treated and scopically, no angioma formation was found in any
phVEGF -treated groups than in the control group (2362 treated-animals or controls. The increased capillary density 165
and 2462% vs. 3764%, P,0.01 and P,0.05, respective- was mainly limited to the area around the infarct area
ly) as shown in Fig. 3. The infarct size was similar (border zone).
between the HIF-1a/VP16-treated and VEGF-treated
groups. The infarction ratio (2063%) was further reduced 3.5. Measurement of regional blood ﬂow
by the combination of pHIF-1a/VP16 and phVEGF . 165
The infarct size was also signiﬁcantly smaller in the Radioactive microspheres were used to measure relative
pHIF-1a/VP16 and phVEGF -treated groups than in the blood ﬂow in four hearts in each group. The right 165
control at day 7 after transfection (data not shown). ventricular free wall, which was noninfarcted in this
model, served as the reference region. The weight of the
3.4. Capillary density left ventricle and the right ventricular free wall in each
heart was about 1.0 and 0.2 g, respectively. In the rat
Given that CD31 antibody speciﬁcally identiﬁes capil- without infarction, the radioactivity of the left ventricle
laries, we used CD31 antibody to detect capillaries at 14 was 2-fold that of the right ventricular free wall. As shown
and 28 days after transfection. Capillary densities observed in Fig. 5, the regional blood ﬂow ratio was signiﬁcantly
in the myocardium of the pHIF-1a/VP16-treated group higher in the treated rats than in the control group. There
2 (850650/mm ) and the phVEGF -treated group was no signiﬁcant difference in relative blood ﬂow among 165
2 (850675/mm ) were signiﬁcantly higher (P,0.01) than the three treated groups.
2 that of the control (550675/mm ) at day 28 after transfec-
tion, as shown in Fig. 4. The capillary density in the group 3.6. HIF-1a/VP16 hybrid increases plasma VEGF level
of combined pHIF-1a/VP16 and phVEGF was sig- 165
niﬁcantly higher than that of either pHIF-1a/VP16-treated As shown in Fig. 6A and B, the plasma VEGF level in
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Fig. 4. Effect of intramyocardial pHIF-1a/VP16 and phVEGF on capillary density. The number of rats was also nine in each group. Photomicrography 165
shows representative immunohistochemical CD31 staining of ischemic myocardium harvested at day 28. Dots (arrow) indicate capillaries.
the HIF-1a/VP16-treated group and the VEGF-treated tion activity but retains a high level of DNA binding that is
group was signiﬁcantly higher than that of the control equivalent in hypoxic and non-hypoxic cells [26]. This
group at days 3 and 7 after coronary ligation. There was no result suggests that both the activation domain and the
statistical difference in VEGF levels between the HIF-1a/ protein region responsible for conferring destabilization
VP16-treated group and the VEGF-treated group. with normoxia are located between aa 390 and aa 826. By
deleting this region of HIF-1a and replacing it with
transactivation domain of herpes simplex virus VP16, the
4. Discussion HIF-1a/VP16 hybrid up-regulates exogenous VEGF ex-
pression in vitro and enhances angiogenesis in rabbit
It has been reported that a deletion mutant of HIF-1a hindlimb ischemia [23]. In this study, we provide the ﬁrst
truncated at aa 390 exhibits severely reduced transactiva- demonstration that intramyocardial administration of HIF-
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Caution should be taken when interpreting our data.
Since the results of histochemical staining with TTC were
not validated by direct histologic examination of the
affected tissues, we could not exclude the possibility that
tissue staining properties were altered by therapy without
prevention of tissue necrosis. Because capillary density
would likely differ importantly in infarcted and noninfar-
cted regions, the amount of each tissue type within samples
might signiﬁcantly inﬂuence study outcome. Measure-
ments of myocardial perfusion reﬂect blood ﬂow to the
entire left ventricle without distinction between ﬂow to
infarct and ﬂow to surviving myocardium. The larger,
better-perfused surviving portion of the myocardium is
likely to dominate ﬂow results. The observed ﬂow in-
creases in hearts treated with HIF-1a/VP16 or phVEGF165
Fig. 5. Effect of intramyocardial pHIF-1a/VP16 and phVEGF on 165 might be due to a larger portion of surviving myocar-
regional myocardial blood ﬂow. The radioactivities in the left ventricle dium—or to myocardial hypertrophy, or to a rise in were expressed per weight of heart tissue as a ratio relative to the activity
myocardial oxygen demand—rather than to a rise in in the right ventricular free wall. *P,0.05 vs. control.
capillary density.
Expressions of human HIF-1a/VP16 and VEGF trans-
1a/VP16 hybrid can enhance angiogenesis in acute genes were detected by RT–PCR in the myocardium. No
myocardial infarction. The evidence of revascularization in gene expression was detected in remote tissues, including
response to administration of HIF-1a/VP16 was observed lung, liver, kidney and brain. Thus, intramyocardial ad-
at anatomical and histological levels. Necropsy examina- ministrations of phVEGF and HIF-1a/VP16 result in 165
tion documented a reduction in infarct size and an increase gene expression limited to the target site. Schwarz et al.
in vascularity at the capillary level that exceeded the demonstrated that angioma formation in the infracted
negative control for both pHIF-1a/VP16 and phVEGF . tissue was found after intramyocardial injection of 500 mg 165
The physiological study also demonstrated that regional of phVEGF in a rat model of myocardial infarction [27]. 165
myocardial perfusion and plasma level of VEGF, evidence We did not ﬁnd any angioma formation in HIF-1a/VP16
for functional gene expression, were higher in the treated and VEGF-treated rats in this study: angioma formation
group than in the control. However, the reduction in infarct may be dose-related. In this study, 50 mg of plasmid was
size, the increase in capillary density, regional myocardial used. A recent study also demonstrated that high levels of
blood ﬂow, and plasma levels of VEGF in pHIF-1a/VP16 VEGF expression caused angioma formation in muscle
and phVEGF were similar. Therefore, the efﬁcacy of tissue, but low VEGF levels did not cause angioma 165
HIF-1a/VP16 hybrid and phVEGF as therapeutic formation [28]. Thus, intramyocardial injection of HIF-1a/ 165
agents in enhancing angiogenesis in acute myocardial VP16 and phVEGF may be feasible in patients with 165
infarction is similar. Combined therapy with HIF-1a/ acute myocardial infarction or with recent infarcts if a
VP16 and VEGF induced more capillary formation than smaller dosage is administered.
either therapy alone, although the infarct size could not be Administration of HIF-1a/VP16 hybrid via gene
further reduced by the combined therapy. therapy may prove to be an effective treatment for
Fig. 6. Plasma VEGF levels measured by enzyme immunoassay. (A) VEGF levels at day 3 after transfection. (B) VEGF levels at day 7 after transfection.
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[11] Jiang BH, Zheng JZ, Leung SW, Roe R, Semenza GL. Transactiva- ischemia associated with vascular disease. In this applica-
tion and inhibitory domains of hypoxia-inducible factor 1a: modula- tion, HIF-1a/VP16 may up-regulate a variety of genes,
tion of transcriptional activity by oxygen tension. J Biol Chem
including VEGF. Clinical beneﬁts may be achieved, not 1997;272:19253–19260.
only as a result of stimulation of angiogenesis, but also [12] Semenza GL. Transcriptional regulation by hypoxia-inducible factor
through additional HIF-1-mediated local adaptations to low 1: molecular mechanisms of oxygen homeostasis. Trends Cardiov-
asc Med 1996;6:151–157. oxygen tension such as vasodilatation, protection from
[13] Bunn HF, Poyton RO. Oxygen sensing and molecular adaptation to oxidant stress, and a transition to anaerobic metabolism
hypoxia. Physiol Rev 1996;76:839–885. [29]. This study demonstrated that intramyocardial in-
[14] Semenza GL, Wang GL. A nuclear factor induced by hypoxia de
jection of plasmid DNA encoding HIF-1a/VP16 was novo protein synthesis binds to the human erythropoietin gene
sufﬁcient to enhance revascularization in a rat model of enhancer at a site required for transcriptional activation. Mol Cell
Biol 1992;12:5447–5454. acute myocardial infarction, although no attempt was made
[15] Wang GL, Semenza GL. Characterization of hypoxia-inducible in this study to determine the corresponding extent of
factor 1 and regulaton of DNA binding activity by hypoxia. J Biol functional improvement. This strategy provides an alter-
Chem 1993;268:21513–21518.
native method for therapeutic angiogenesis by exploiting a [16] Semenza GL, Agani F, Booth G et al. Structural and functional
transcriptional regulatory system. These ﬁndings may have nalysis of hypoxia-inducible factor 1. Kidney Int 1997;51:553–555.
important practical implications for the treatment of pa- [17] Jiang BH, Semenza GL, Bauer C, Marti HH. Hypoxia-inducible
factor 1 levels vary exponentially over a physiological relevent tients with severe myocardial ischemia.
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